By contrast, we previously showed that DOK7 gene therapy greatly facilitates NMJ enlargement in the appropriate central region of myofibers without lethal effects for more than 1 year in DOK7 myasthenia model mice (Arimura et al, 2014), suggesting that DOK7 gene therapy is a safer therapeutic approach. The gene discussed is DOK7; the disease is Fatigable weakness.